News
RECORDATI BOARD APPROVES THE 2022 ACCOUNTS, CONFIRMING STRONG CONSOLIDATED FINANCIAL RESULTS: REVENUE +17.3%, EBITDA(1) +11.7%, ADJUSTED NET INCOME(2) +11.5% 2022 DIVIDEND € 1.15 (+4.5%)
Read more here
Recordati completes the acquisition of EUSA Pharma (UK)
Read more here
Recordati to acquire EUSA Pharma (UK) Ltd, a global specialty pharmaceutical company focused on rare and niche oncology diseases
Read more here